Homocysteine and oxidative stress in acute stroke*

Laura Nanetti¹†, Arianna Vignini¹†, Francesca Raffaelli¹, Alessia Giulietti¹, Marco Bartolini², Cecilia Perozzi², Mauro Silvestrini², Leandro Provinciali², Laura Mazzanti¹

¹Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, Ancona, Italy
²Department of Clinical Science, Biochemistry Section, Università Politecnica delle Marche, Ancona, Italy
Email: †l_nanetti@hotmail.com

Received 2 August 2013; revised 15 September 2013; accepted 1 October 2013

ABSTRACT
Homocysteine (Hcy) is a sulfhydryl-containing amino acid derived from the essential amino acid methionine. Total Hcy (tHcy) plasma level varies in the range of 5 - 15 μmol/L in the normal population. Our aim in this study was to investigate the possible correlations among homocysteine plasma levels, oxidative stress parameters and clinical evolution of stroke. Fifty patients with large-vessel ischemic stroke were studied. Biochemical determinations were performed at entry (T0) and then repeated one month after stroke (T1). Homocysteine levels were significantly increased at T0 with respect to T1 and showed a significant positive correlation with the expression of oxidative stress markers and a negative correlation with indicators of protective anti stress activity. A significant increase of antioxidant activity occurred from T0 to T1 and changes were associated with the severity of clinical conditions. In particular, the extent of homocysteine and of oxidative stress markers plasmatic levels reduction and of the contemporary increase in anti stress biochemical activities were associated with a reduction of NIHSS scores. These findings, besides confirming an involvement of oxidative stress in influencing the evolution of stroke, suggest a role for homocysteine as a potentially modifiable biochemical alteration able to modulate some mechanisms involved in the production of ischemic damage.

Keywords: Homocysteine; Acute Stroke; Oxidative Stress; Platelets

1. INTRODUCTION
Homocysteine (Hcy) is a sulfhydryl-containing amino acid derived from the essential amino acid methionine, which is abundant in animal sources of protein [1]. Total Hcy (tHcy) plasma level varies in the range of 5 - 15 μmol/L in the normal population [2]. Minor genetic abnormalities or nutritional deficiencies of B vitamins, such as folic acid involved in methionine metabolism, can lead to increased tHcy concentration. The involvement of homocysteine in atherosclerosis was first promulgated by McCully on the basis of his pathological findings in infants with hyperhomocysteinemia resulting from inborn metabolism deficiency [3]. In experimental studies, homocysteine causes oxidative stress and vascular inflammation, damages endothelial cells, inhibits endothelium-dependent relaxation, and enhances thrombogenicity [4]. A large body of epidemiological studies suggest that increased homocysteine level may be considered as an independent risk factor for vascular diseases, including stroke [5-7].

Ischemic stroke is a heterogeneous syndrome caused by multiple disease mechanisms, resulting in a disruption of cerebral blood flow with subsequent tissue damage. The extent of focal cerebral injury is influenced by different molecular mechanisms. An alteration of the physiologic balance between production and degradation of enzymatic activity involved in the regulation of tissue oxidative status may play a role in influencing the results of the ischemic condition [8,9]. A recent study by our group proposed that cerebral ischemia causes the release of nitric oxide (NO) from the vascular endothelium. An elevated circulating concentration of the sulfur-containing amino acid homocysteine, hyperhomocysteinemia, produces complex changes within blood vessels. In the peripheral circulation, these changes include oxidative stress. Hyperhomocysteinemia-induced oxidative stress may occur as a result of decreased expression and/or activity of key antioxidant enzymes as well as increased enzymatic generation of superoxide anion (the precursor for multiple reactive oxygen and reactive nitrogen spe-
The aim of this study was to analyze changes in homocysteine levels in ischemic stroke patients in the acute phase and after a month from disease onset. Furthermore, we investigated the possible correlations among homocysteine values, oxidative stress parameters and clinical evolution.

2. PATIENTS AND METHODS

Fifty patients with large-artery ischemic stroke [10] admitted to the Stroke Unit of the Neurological Clinic of the Marche Polytechnic University were enrolled. All subjects gave informed consent prior to the drawing of peripheral venous blood. The study was performed in accordance with the principles contained in the Declaration of Helsinki as revised in 2001, and the study was approved by the Bioethical Committee of the Marche Polytechnic University. The diagnosis of stroke was based on the presence of an acute-onset, persistent focal neurological deficit [11]. The diagnosis was then confirmed through CT scan within 24 hours from onset. Exclusion criteria were: previous stroke, evidence on CT of hemorrhagic cerebral lesion, neoplastic disease, chronic condition potentially able to influence oxidative status like severe cardiac, liver or renal failure, embolizing cardiopathies and current treatment with statins. Patients with clinical or neuroradiological evidence of lacunar infarction were also excluded in order to reduce the heterogeneity of our study population. In this respect, in a previous study, we demonstrated that changes in some oxidative stress markers are significantly lower in patients with lacunar stroke compared to large-vessel stroke patients [12]. Patients with dementia or other conditions hindering the possibility of obtaining consent to participate in the study were also excluded.

No included patient was observed within the time-window suitable for fibrinolysis treatment.

Demographic characteristics, vascular risk profile and Oxfordshire Community Stroke Project classification of included patients are shown in Table 1. Metabolic parameters of patients at T0 and T1 are shown in Table 2.

Homocysteine levels of subjects with stroke were compared with 34 control subjects matched for age (18 men, 16 women 66 ± 8 Hcys 9.4 ± 2 µmol/L, fibrinogen 220 ± 11). Biochemical determinations were performed at entry (T0) and then repeated one month after stroke (T1). Stroke severity on admission and at T1 was assessed with the National Institute of Health Stroke Scale (NIHSS) [11]. We used clinical parameters to characterize stroke severity, since the study design did not include a neuroradiological investigation performed with the appropriate time and modality to exactly measure the final extension of the ischemic lesion. For this reason CT data were only used to support the diagnosis of large artery stroke.

3. PLATELET ISOLATION

Peripheral venous blood was drawn after overnight fasting, and immediately mixed with Anticoagulant Citrate Dextrose (ACD) (36 ml citric acid, 5 mM KCl, 90 mM NaCl, 5 mM glucose, 10 mM EDTA, pH 6.8). Platelets were isolated by differential centrifugation in anti-aggregation buffer (Tris-HCl 10 mm; NaCl 150 mm; EDTA 1 mm; glucose 5 mm; pH 7.4) according to Vignini et al. [13]. The method involved a preliminary centrifugation step (200 × g for 10 min) to obtain platelet-rich plasma (PRP). The platelets were then washed three times in anti-aggregation buffer and centrifuged as above in order to remove any residual erythrocytes. A final centrifugation at 2000 × g for 20 min was performed to isolate the platelets. The platelet pellet was washed twice in phosphate buffered saline PBS (containing NaCl 135 mM, KCl 5 mM, EDTA 10 mM, Na3PO4 8 mM, NaH2PO4 H2O 2 mM, pH 7.2) and immediately used for the experiments or stored at −80°C.

Homocysteine levels were evaluated using a Microparticle Enzyme Immunoassay method with IMx (Abbott Diagnostic, Germany). Using this method, levels
<15 \mu mol/L were considered normal.

4. NO PRODUCTION

NO platelet production was evaluated by Assay Designs™ Total Nitric Oxide Assay Kit (Catalog No. 917020; 192 Determination Kit); this commercial kit is complete for quantitative determination of total NO in biological fluids. The kit involves the enzymatic conversion of nitrate to nitrite, by the enzyme Nitrate Reductase, followed by the colorimetric detection of nitrite as a colored azo dye product of the Griess reaction [14] that absorbs visible light at 540 nm. The modified protocol which employs deproteinization and reduction of nitrates to nitrites in the presence of NADPH-sensitive reductase, prior to addition of the Griess reagent, allows measurement of combined nitrite (NO$_2^-$) and nitrate (NO$_3^-$) (recently named together as NOx) and can be successfully applied for measurement of NO levels in human body fluids [15]. Since all products of NO and its derived species ultimately give only NO$_2^-$ and NO$_3^-$, this modified Griess reaction allows a quantitative tally of all NO produced during a given period [16]. In this assay equal amounts of 1% sulphonylic acid and 0.1% N-(1-naphthyl) ethylene diamine were added to the samples and the resulting absorbance was measured at 543 nm. Blank (background) was determined in each experiment utilizing medium incubated without a sample. The amount of NOx in each sample was determined using a standard curve generated with known concentrations of NOx and expressed as nmol NOx/mg protein. Protein concentration was determined by Bradford BioRad protein assay, using serum albumin as a standard to normalize the NOx concentration data [17].

This assay can be performed in a conventional spectrophotometer using 96-well microtiter plates, (provided with the kit) which require less sample volume and offer increased speed, throughput, and precision (due to simultaneous measurement of all standards and unknowns).

5. PEROXYNITRITE PRODUCTION

Peroxynitrite production in platelets was evaluated using the fluorescence probe 2,7-Dichlorofluorescein diacetate (DCFDA) as previously described [18]. DCFDA free base was prepared daily, by mixing 0.05 mL of 10 mmol/L DCFDA with 2 mL of 0.01 N NaOH, at room temperature for 30 min. The mixture was neutralized with 18.0 mL of 25 mmol/L phosphate-buffered saline (PBS) pH 7.4; this solution was maintained on ice in the dark until use [19].

Briefly, platelets were incubated for 15 min with 5 mM DCFDA-free base at 37°C. Then the DCFDA-treated platelets were divided into two sets: one set was incubated with the addition of a mixture of L-arginine 100 mM and NG-monomethyl-L-arginine (L-NMMA) 100 mM for 15 min at 37°C in the dark while the other set was incubated with the above mentioned mixture but only with PBS. After washing platelets twice in PBS (25 mmol/L) pH 7.4, samples were sonicated to brake platelet pellets. The mixture was then centrifuged at 200 × g for 5 min and the fluorescence was measured in the supernatant in a Perkin-Elmer LS-50B spectrofluorometer, at an excitation wavelength of 475 nm and emission wavelength of 520 nm. Blank samples contained all reagents except platelets. Fluorescence results obtained after L-NMMA incubation were subtracted from those without L-NMMA. ONOO-production was corrected by protein concentration and was expressed in arbitrary fluorescence numbers/mg prot.

6. TOTAL ANTIOXIDANT CAPACITY (TAC)

Total antioxidant capacity was evaluated with a Biovision Assay kit. Biovision has developed a TAC Assay kit which can measure either the combination of both small molecule antioxidants and proteins or small molecules alone in the presence of Protein Mask. Cu$^{2+}$ ion is converted to Cu$^+$ by both small molecules and proteins. The Protein Mask prevents Cu$^{2+}$ reduction by proteins, enabling the analysis of only the small molecule antioxidant. The reduced Cu$^+$ ion is chelated with a colorimetric probe giving a broad absorbance peak of around 570 nm, proportional to the total antioxidant capacity. Aliquots of frozen plasma were thawed at room temperature, and 10 µL of the samples were tested immediately. 10 µL of Protein Mask was added in a plate. The reaction was started directly in the plate with 100 µL of Cu$^{2+}$ working solution. Plates were covered and incubated at room temperature for 1.5 hours. Trolox, a water-soluble toco-pherol analog, was used as a reference standard. Standard curves were obtained by using increasing concentrations of Trolox in the same volume as for the sample. Absorbance was measured with a Hewlett-Packard 8450 A UV/Visible spectrophotometer equipped with a cuvette stirring apparatus and a constant temperature cell holder.

Unless stated differently, experiments were repeated 2 to 3 times. Qualitatively, similar results were obtained with individual values varying by less than 8%.

In the lag mode, the assay mainly measures nonprotein and nonenzymatic antioxidants that are primarily extracellular chain-breaking ones, such as ascorbate, urate, and glutathione.

Plasma Lipid hydroperoxides were evaluated by measuring the levels of hydroperoxides using the ferrous oxidation xylene orange assay (FOX-assay) in agreement with our previous studies [20]. Samples were incubated with FOX reagent (100 mmol/L xylene orange, 250
mmol/L Fe2+, 25 mM H2SO4, and 4 mmol/L BHT in 90% methanol (v/v), then centrifuged at 4500 rpm for 20 min. The absorbance of the supernatant was determined at 560 nm and hydroperoxide levels were calculated using the molar coefficient $(4.3 \times 10^{4} M^{-1} cm^{-1})$ [20].

7. SUSCEPTIBILITY TO OXIDATIVE STRESS IN VITRO

The susceptibility to peroxidation was determined by measuring the production of thiobarbituric acid-reactive substances (TBARS) after incubation. Plasma was incubated at 37°C for 18 h with a freshly prepared CuSO4 solution added to the final concentration of 10 μM to a solution containing 1 mg/ml of VLDL or HDL protein. Susceptibility to peroxidation was determined by measuring the production of thiobarbituric acid-reactive substances (TBARS) after incubation. The degree of lipoprotein oxidation was determined by measuring lipoperoxide level (TBARS) before and after peroxidative stress [21]. TBARS were determined using the Yagi et al. method [22]. Results are expressed as nanomoles malondialdehyde per 100 μg protein. Proteins were measured by the Bradford method [17]. Oxidizability was determined as the difference in TBARS content before and after incubation with CuSO4.

8. DETERMINATION OF CONJUGATED DIENES

Conjugated dienes were assayed by monitoring the increase in absorbance at 234 nm as described previously [23].

Figure 1. Homocysteine levels during an ischemic attack (T0) and after one month (T1). Results are expressed as means ± SD, (p < 0.001).

9. STATISTICAL ANALYSIS

Statistical analysis was performed using the SAS statistical package (Statistical Analysis System Institute, Cary, NC, USA). All results are expressed as mean ± SD. ANOVA was used to analyze the difference of results obtained in different experimental conditions. Differences were considered significant with p < 0.05. Moreover, a linear correlation between Homocysteine and Fibrinogen, TAC and all oxidative stress parameters was used in order to observe a possible significant correlation. Differences were considered significant with p < 0.05.

10. RESULTS

Homocysteine values were significantly lower after one month (T1) from ischemic attack compared to stroke onset (T0) (Figure 1).

Moreover a significant positive correlation was found (Figure 2(a)) between Homocysteine and NIHSS score at T0 and T1 ($r = 0.849$, $p < 0.001$ T0, and $r = 0.684$ $p < 0.001$ T1) and between homocysteine and fibrinogen ($r = 0.756$, $p < 0.001$ T0, and $r = 0.747$ $p < 0.001$ T1) (Figure 2(b)), accompanied by a significant positive correlation between Homocysteine and peroxynitrite ($r = 0.957$, $p < 0.001$ T0, and $r = 0.915$ $p < 0.001$ T1) (Figure 2(c)), hydroperoxide ($r = 0.846$, $p < 0.001$ T0, and $r = 0.740$ $p < 0.001$ T1), (Figure 2(b)), lipoperoxide ($r = 0.758$, $p < 0.001$ T0, and $r = 0.806$ $p < 0.001$ T1) (Figure 2(c)), and conjugates dienes ($r = 0.888$, $p < 0.001$ T0, and $r = 0.817$ $p < 0.001$ T1) (Figure 2(d)), at T0 and T1. On the other hand, a significant negative correlation between homocysteine and Nitric oxide ($r = -0.965$ at T0, $p <
Figure 2. (a) Positive correlation between Homocysteine (TAC) and NIHSS score at T0 (■) and T1 (□) \( (r = 0.849, p < 0.001 \text{ T0, and } r = 0.684 \ p < 0.001 \text{ T1}) \); (b) Positive correlation between Homocysteine and fibrinogen at T0 (■) and T1 (□) \( (r = 0.756, p < 0.001 \text{ T0, and } r = 0.747 \ p < 0.001 \text{ T1}) \).
are important players in the etiology of atherosclerotic plaque formation. These actions may justify the promoting action of increased plasmatic concentration of homocysteine on cerebrovascular diseases.

The present study provides some information about the mechanisms of oxidative stress in stroke and the role of Hcys.

In fact, our results suggest that elevated levels of Hcys at stroke onset may actively participate in the pathogenesis and evolution of ischemic damage (Figure 1) probably by an interference in mechanisms regulating oxidative stress.

The mechanism by which homocysteine promotes the production of hydroxyl radicals and lipid peroxidation initiators may be related to the reactivity of the sulphydryl group leading to homocysteine autooxidation and thiolactone formation. Thus mild to moderate hyperhomocysteinemia, even though not atherogenic per se, may lead to increased stroke severity as well as other classical risk factors [28].

In fact, in our study, Hcy levels increased stepwise with increasing NIHSS class, revealing a significant correlation between Hcy levels and NIHSS class severity of stroke both at onset and after 1 month.

Our finding of a parallel increase/decrease of Hcys and fibrinogen level at T0 and at T1 respectively, also suggested a possible role of Hcys in the modulation of the coagulation and fibrinolysis system. Other relevant findings were the significant positive correlation at T0 and T1 between Hcy levels and ONOO$^-\quad$hydroperoxidation, lipoperoxidation, and conjugated diene. On the contrary, Hcy levels showed a significant negative correlation with NO levels and TAC.

Peroxynitrite (formed by the reaction of NO with superoxide) increases in peripheral blood vessels during hyperhomocysteinemia [4]. Peroxynitrite is known to activate poly (ADP-ribose) polymerase (PARP). Activation of PARP may be an important mediator of vascular dysfunction in other disease states such as diabetes. Homocysteine is also known to activate PARP, at least in
neurons, suggesting that PARP may potentially be involved in cerebral vascular dysfunction during hyperhomocysteinemia. Peroxynitrite can also produce vascular dysfunction and oxidative stress through nitration of protein tyrosine residues and promote the uncoupling of NO synthases, a circumstance in which the normal flow of electrons within NO synthase produces superoxide ions rather than NO [29].

In fact, a previous study suggested an involvement of oxidative stress mechanisms during the development of ischemic injury after stroke. The levels of lipoperoxide, hydroperoxide and diene conjugates resulted significantly higher at the time of the acute event than after a month [30].

This evolution seems to be influenced by the activation of endogenous compensatory mechanisms, as suggested by a significant increase of Total Antioxidant Capacity (TAC) from T0 to T1.

The significant correlation between oxidative stress markers levels and Hcy levels found in the present study suggests that Hcy levels control could positively interact with some of the pathological changes involved in the evolution of cerebral ischemic damage.

This concept seems to be reinforced by the negative correlation between HCY levels and NO and TAC at T0 and T1. In fact, this finding is in accordance with the hypothesis that increased homocysteine levels reduce defensive mechanisms against damaging effects of free
In conclusion, our data, obtained in a subgroup of patients with large-artery stroke, suggest an involvement of homocysteine in the pathogenesis of ischemic damage. In this respect, besides the possible use of hyper-Hcy as a prognostic marker, acute therapeutic interventions aimed at modulating Hcy levels should be considered as a further therapeutic strategy in patients with ischemic stroke, in the attempt to positively interfere with the biochemical mechanisms involved in oxidative stress.

REFERENCES


